Publication | Closed Access

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerSequential Therapy